Levels of Evidence Supporting United States Guidelines in Pancreatic Adenocarcinoma Treatment
Cancer guidelines are ideally based on high levels of evidence (LOE). We aim to evaluate the LOE supporting recommendations in United States (US) guidelines on pancreatic adenocarcinoma (PDAC) treatment and its evolution over time. We searched for current guidelines from the American Society of Clin...
Main Authors: | Anna Pellat, Isabelle Boutron, Romain Coriat, Philippe Ravaud |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/16/4062 |
Similar Items
-
Management of Metastatic Pancreatic Cancer—Comparison of Global Guidelines over the Last 5 Years
by: Monika Pajewska, et al.
Published: (2023-09-01) -
Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
by: Victor Mortier, et al.
Published: (2022-12-01) -
Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)
by: Nicola Silvestris, et al.
Published: (2020-06-01) -
The use of the level of evidence and grade of recommendations scales in developing clinical guidelines in the Russian Federation
by: N. I. Zhuravleva, et al.
Published: (2019-05-01) -
Diagnostic Yield of Repeat Endoscopic Ultrasound-Guided Fine Needle Biopsy for Solid Pancreatic Lesions
by: Baptiste Camus, et al.
Published: (2023-07-01)